Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/54794
Full metadata record
DC FieldValueLanguage
dc.contributor.authorS. Lekawanvijiten_US
dc.contributor.authorH. Krumen_US
dc.contributor.authorS. Lekawanvijiten_US
dc.date.accessioned2018-09-04T10:23:34Z-
dc.date.available2018-09-04T10:23:34Z-
dc.date.issued2015-01-01en_US
dc.identifier.other2-s2.0-84942530100en_US
dc.identifier.other10.1007/978-3-319-09162-4_19en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84942530100&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/54794-
dc.description.abstract© Springer International Publishing Switzerland 2015. Due to a significant burden of the common coexistence of chronic kidney disease (CKD) and cardiovascular disease (CVD) as well as their complex pathophysiological interplay, the concept of integrated cardiorenal pathology has been increasingly recognized. A continuing increase in prevalence of CKD has become a global health concern. One of the major consequences of the growing CKD population is a further deterioration of the CVD epidemic. CKD patients are at extraordinarily high risk for CVD; and CVD in turn is the single most common cause of death in the CKD population, especially in the dialysis-dependent subgroup. Interestingly, traditional cardiovascular risk factors are not sufficient to explain the high prevalence of CVD in this population. There have thus been major efforts in search of novel risk factors specific or closely-related to the CKD milieu. Evidence of non-dialyzable protein-bound uremic toxins as potential risk factors for CKD-associated cardiovascular pathology and mortality as well as potential strategies targeting these toxins has emerged in recent years. At present, indoxyl sulfate and p-cresyl sulfate are the two most problematic toxins with regard to their negative cardiorenal impact. Along with ongoing development in dialysis technique to improve removal of these toxins, novel therapies that reduce the production of such toxins offer a potential approach to alleviating, or even preventing, their toxic effects on heart and kidney.en_US
dc.subjectMedicineen_US
dc.titleNovel combination therapy to target heart and kidneyen_US
dc.typeBooken_US
article.title.sourcetitleCardio-Renal Clinical Challengesen_US
article.stream.affiliationsChiang Mai University Hospitalen_US
article.stream.affiliationsAlfred Hospitalen_US
article.stream.affiliationsChiang Mai Universityen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.